|Getting Help With Non-Hemolytic Hyperbilirubinemia.|
Hyperbilirubinemia remains a challenge for all who care for newborns. Despite the wonders of transcutaneous bilirubin (TcB) measures, when the TcB is high (and we can debate exactly which number is the trigger) a blood level is likely appropriate.2,3 ...
AAP News - Wed, 11 Nov 2015 08:30
|Increased asymmetric dimethylarginine levels in severe transient tachypnea of ...|
35 weeks GA with indirect hyperbilirubinemia, from whom blood was drawn for follow-up of bilirubin levels, were enrolled as controls. GA was calculated according to the last maternal menstrual period, early pregnancy ultrasound examination findings or ...
Nature.com - Thu, 11 Feb 2016 05:52
|Neonatal Hyperbilirubinemia: Study Identifies Risk Profile|
A set of maternal and obstetric risk factors readily available at birth predicts a greater than 100-fold variation in the incidence of nonhemolytic neonatal hyperbilirubinemia, according to a large population-based study published online November 9 in ...
Medscape - Mon, 09 Nov 2015 03:32
|Clinical Review: Regorafenib in Refractory mCRC|
The most frequent drug-related grade ≥3 AEs were HFSR (16%), hypertension (11%), hyperbilirubinemia, hypophosphatemia, and alanine aminotransferase increase (7%, each). “The studies showed that regorafenib improved overall survival in both Asian ...
Targeted Oncology - Wed, 10 Feb 2016 23:07
|Dad Shares Photo of Baby's First Bath But It's Not Her Look That Causes ...|
According to the Children's Hospital of the King's Daughters website, hyperbilirubinemia is neonatal jaundice. This can occur in up to 60% of newborns. It can be detected by the “yellow coloring of the skin and whites of the eyes” and is commonly seen ...
IJ Review - Fri, 22 Jan 2016 09:03
|Low-cost filtered-sunlight therapy noninferior to conventional phototherapy in ...|
Study Rundown: Severe neonatal hyperbilirubinemia, often leading to kernicterus and devastating neurologic outcomes, affects almost half a million infants annually. It disproportionately affects those in sub-Saharan Africa. Standard treatment of this ...
2 Minute Medicine - Mon, 28 Sep 2015 03:30
|Exelixis Announces European Medicines Agency Acceptance of Marketing ...|
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) for cabozantinib as a treatment for patients ...
Business Wire (press release) - Thu, 28 Jan 2016 13:00
|Baxalta Granted EU Marketing Authorization for ONCASPAR (pegaspargase) as a ...|
The most common adverse reactions with ONCASPAR (≥2%) are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) toxicity, thrombosis, coagulopathy, hyperbilirubinemia and elevated transaminases.
Business Wire (press release) - Tue, 19 Jan 2016 03:37